Please use this identifier to cite or link to this item:
Title: DHA intake relates to better cerebrovascular and neurodegeneration neuroimaging phenotypes in middle-aged adults at increased genetic risk of Alzheimer disease
Author: Sala Vila, Aleix
Arenaza Urquijo, Eider M.
Sánchez Benavides, Gonzalo
Suárez Calvet, Marc
Milà Alomà, Marta
Grau Rivera, Oriol
González de Echávarri, José M.
Crous Bou, Marta
Minguillón, Carolina
Fauria, Karine
Operto, Grégory
Falcón, Carles
Salvadó, Gemma
Cacciaglia, Raffaele
Ingala, Silvia
Barkhof, Frederik
Schröder, Helmut
Scarmeas, Nikolaos
Gispert, Juan Domingo
Molinuevo, José Luis
The Alfa Study
Keywords: Malaltia d'Alzheimer
Factors de risc en les malalties
Alzheimer's disease
Risk factors in diseases
Issue Date: 18-Mar-2021
Publisher: Oxford University Press (OUP)
Abstract: Background: The number of APOE-ε4 alleles is a major nonmodifiable risk factor for sporadic Alzheimer disease (AD). There is increasing evidence on the benefits of dietary DHA (22:6n-3) before the onset of AD symptoms, particularly in APOE-ε4 carriers. Brain alterations in the preclinical stage can be detected by structural MRI. Objectives: We aimed, in middle-aged cognitively unimpaired individuals at increased risk of AD, to cross-sectionally investigate whether dietary DHA intake relates to cognitive performance and to MRI-based markers of cerebral small vessel disease and AD-related neurodegeneration, exploring the effect modification by APOE-ε4 status. Methods: In 340 participants of the ALFA (ALzheimer and FAmilies) study, which is enriched for APOE-ε4 carriership (n = 122, noncarriers; n = 157, 1 allele; n = 61, 2 alleles), we assessed self-reported DHA intake through an FFQ. We measured cognitive performance by administering episodic memory and executive function tests. We performed high-resolution structural MRI to assess cerebral small vessel disease [white matter hyperintensities (WMHs) and cerebral microbleeds (CMBs)] and AD-related brain atrophy (cortical thickness in an AD signature). We constructed regression models adjusted for potential confounders, exploring the interaction DHA × APOE-ε4. Results: We observed no significant associations between DHA and cognitive performance or WMH burden. We observed a nonsignificant inverse association between DHA and prevalence of lobar CMBs (OR: 0.446; 95% CI: 0.195, 1.018; P = 0.055). DHA was found to be significantly related to greater cortical thickness in the AD signature in homozygotes but not in nonhomozygotes (P-interaction = 0.045). The association strengthened when analyzing homozygotes and nonhomozygotes matched for risk factors. Conclusions: In cognitively unimpaired APOE-ε4 homozygotes, dietary DHA intake related to structural patterns that may result in greater resilience to AD pathology. This is consistent with the current hypothesis that those subjects at highest risk would obtain the largest benefits from DHA supplementation in the preclinical stage.This trial was registered at as NCT01835717.
Note: Reproducció del document publicat a:
It is part of: The American Journal of Clinical Nutrition, 2021, vol. 113, num. 6, p. 1627-1635
Related resource:
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
nqab016.pdf497.01 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons